Search for: "In re Sambrano" Results 1 - 7 of 7
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Mar 2014, 2:47 pm by David Jensen
He also said the CIRM staff's re-examination of the scientific issues was inadequate.Marban did not disclose specifics of his complaints about the nature of the conflict. [read post]
11 Mar 2014, 2:00 am by David Jensen
Since the objectives of the proposed and currently enrolling trials are similar, reviewers agreed that the proposed Phase 1 trial does not add value and should be re-evaluated after completion and analysis of data from the current trial . [read post]
26 May 2020, 6:31 am by David Jensen
(Gil) Sambrano (CIRM vice president for portfolio development) noted, stem cells are ubiquitous in the body, and I took that to mean that one could either be elastic or inelastic in accepting products. [read post]
9 Feb 2014, 6:18 am by David Jensen
California Stem Cell Report: Are there processes at CIRM that show weaknesses or need to be re-examined? [read post]
12 Jan 2015, 5:28 am by David Jensen
See the agenda for specific addresses.Gil Sambrano continues to head the review process, albeit with a new title: director of portfolio development and review. [read post]